Cartesian Q1 2024 net loss $56.8M; cash $104.8M; MG Phase 2b data on track for mid-2024

Cartesian Therapeutics, Inc.

2024-Q1 EPS reported -$10.50 revenue$5,840,000

Net loss $56.8M ($10.50/shr) vs $21.7M ($4.24/shr) Q1 2023; loss widened on higher G&A from merger.
Cash, equivalents, restricted cash $104.8M; expected to fund operations into 2H 2026.
R&D expenses $9.7M (down from $18.6M) on pipeline reprioritization; G&A $9.5M (up from $5.7M) on merger costs.
Phase 2b topline for Descartes-08 in myasthenia gravis expected mid-2024; SLE Phase 2 dosing starts Q2 2024.
Completed 1-for-30 reverse stock split and preferred conversion; new Maryland HQ expanding manufacturing.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cartesian Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-24-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.